Evidence map›Paper›PMID 41816857›Full record

ArticleDiabetes, obesity & metabolism2026

Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide.

Hamlet Gasoyan, Rebecca Schulte, Christopher B Boyer, Nicholas J Casacchia, W Scott Butsch, Phuc Le, Ali Aminian, Marcio L Griebeler, Bartolome Burguera, Michael B Rothberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hamlet GasoyanCenter for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.ORCID 0000-0002-1627-9777
Rebecca SchulteDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Christopher B BoyerDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Nicholas J CasacchiaCenter for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.
W Scott ButschDepartment of Surgery, Bariatric and Metabolic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Phuc LeCenter for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Ali AminianDepartment of Surgery, Bariatric and Metabolic Institute, Cleveland Clinic, Cleveland, Ohio, USA.ORCID 0000-0001-5756-9917
Marcio L GriebelerDepartment of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.
Bartolome BurgueraDepartment of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.
Michael B RothbergCenter for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Funding

Cleveland Clinic - Jack, Joseph and Morton Mandel Accelerator Grants MAG0030
6 · The paper itself

Abstract

aimsTo describe obesity treatments in real-world settings after discontinuation of semaglutide or tirzepatide and variability in weight change post-discontinuation. MATERIALS AND

methodsThis retrospective cohort study used electronic health records from 1 January 2021, to 30 June 2025, in a large health system in Ohio and Florida. Adults with overweight or obesity who initiated injectable semaglutide or tirzepatide for obesity or T2D between 2021 and 2023 and discontinued the medication within 3-12 months were included. Main outcomes were reinitiation of the index medication or receipt of an alternative treatment, body weight changes from baseline to index medication discontinuation and from discontinuation to 1-year post discontinuation.

resultsA total of 7938 patients (mean [SD] age, 55.7 [13.4] years; 5061 [63.8%] female) were identified. During 1-year post-discontinuation, 19.6% restarted the index medication and 35.2% received an alternative obesity treatment, including starting another medication (27.4%), lifestyle modification visit (13.7%) and metabolic and bariatric surgery (0.6%). Mean percentage weight change from baseline to discontinuation was -8.4% [95% CI, -8.7%, -8.1%] when treating obesity and -4.4% [95% CI, -4.7%, -4.2%] when treating T2D. Mean percentage weight change from discontinuation to 1 year later was 0.5% [95% CI, 0.0%, 1.0%] when treating obesity and -1.3% [95% CI, -1.6%, -1.0%] when treating T2D; however, there was considerable individual-level variability.

conclusionIn this large sample of patients who discontinued semaglutide or tirzepatide, reinitiation of the original medication or receipt of alternative obesity treatment was common. The average weight change 1-year post-discontinuation was relatively small; however, there was considerable individual-level variability.

Indexed as

Anti-Obesity AgentsGlucagon-Like PeptidesObesityAdultAgedDiabetes Mellitus, Type 2FemaleFloridaHumansMaleMiddle AgedOhioRetrospective StudiesSemaglutideTirzepatideWeight LossAnti-Obesity AgentsGlucagon-Like PeptidesSemaglutideTirzepatideglucagon‐like peptide‐1 receptor agonistlifestyle modificationlong‐term weight outcomesmetabolic and bariatric surgeryobesity pharmacotherapytreatment discontinuation

Identifiers

PMID41816857
PMCPMC13146129

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.